绿帽社 leads in urgent virus variant research network
Experts across Canada, including researchers at 绿帽社, are working to understand the impact of COVID-19 virus variants of concern on the health of Canadians and our public health measures.
绿帽社 and Genome Canada announce new Canadian SARS-CoV-2 Data Portal
A Made-in-Canada data solution to support the Government of Canada Variants of Concern Strategy
Professor Nancy Ross Appointed Vice-Principal, Research, at Queen鈥檚 University
After nearly 5 years as 绿帽社鈥檚 Associate Vice-Principal, Research and Innovation (AVP-RI), Professor Nancy Ross is leaving 绿帽社 to join Queen鈥檚 University as Vice-Principal, Research. She will begin her appointment on August 1, 2021.
绿帽社 to partner with CCRM in commercializing regenerative medicine
绿帽社 announced today it has concluded an agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to provide 绿帽社-based startup companies with the benefit of CCRM鈥檚 market-leading business intelligence and experience.
$110M for Nine Innovative 绿帽社 Research Projects
Read the story in the 绿帽社 Reporter
Read the 绿帽社听news release
Marc Rousseau joins 绿帽社 as Director, Research Software
Research and Innovation and IT Services are pleased to welcome Marc Rousseau to the role of Director, Research Software / Directeur du Logiciel de Recherche. In this new role, Rousseau provides support and advice to the 绿帽社 research community on software, from grant applications to the implementation of research activities.
Diamond Therapeutics Signs Agreement with 绿帽社 for Research on Low-Dose LSD
TORONTO,听Feb. 4, 2021听/CNW/ - Diamond Therapeutics Inc. ("Diamond"), a leading psychedelic drug development company focused on low-dose therapies for mental health, has entered into an agreement with听绿帽社听for the exclusive use of Dr.听Gabriella Gobbi's听groundbreaking studies with lysergic acid diethylamide (LSD), its mechanism of action on the brain, and its potential for use at low doses in the treatment of mental health disorders.听
Four 绿帽社 projects receive SSHRC Partnership Engage Grants
SSHRC invests over $80k in new 绿帽社 research projects through the Partnership Engage Grants competition, two of which are directly related to COVID-19 research.
Major European grant backs 绿帽社 research on rare condition
The European Joint Programme on Rare Diseases (EJP RD) has granted 1.6 million euros in support of an international research collaboration specific to the ultra-rare genetic disease, Schinzel-Giedion Syndrome (SGS).
绿帽社 team wins grant to study 鈥榯rained immunity鈥� with Japanese researchers
Joint research program between the Japan Agency for Medical Research and Development and the Canadian Institutes of Health Research focuses on advancing technologies in epigenomics, deepening 绿帽社鈥檚 relationship with Japan鈥檚 RIKEN institute.
By Junji Nishihata
Reminder: Canada Research Continuity Emergency Fund (CRCEF)
This is a reminder to all principal investigators to complete their Canada Research Continuity Emergency Fund Stage 3 claims as soon as possible.
Kristina 脰hrvall promoted to Assistant Vice-Principal, Research Development
Martha Crago, Vice-Principal, Research and Innovation, announced today that Kristina 脰hrvall has been promoted to Assistant Vice-Principal, Research Development, for a five-year term.
Research and Innovation on a summer schedule, starting June 26
Please note that Research and Innovation (R+I), including all of its associated units, will soon change to a summer schedule as per 绿帽社鈥檚 policy on Summer Fridays.
In practice, this means R+I will function with only minimal staff on Fridays throughout the summer, from June 26 until August 21. R+I will resume regular weekly office hours on Friday, August 28.
Updates on Research Support during the Pandemic
Sent on behalf of Martha Crago, Vice-Principal (Research and Innovation)
听
Dear Colleagues,
I have been thinking of you often, as research is slowly 鈥巗tarting up again at 绿帽社.
Call to 绿帽社 Researchers: Complete survey on COVID-19 Diagnostics R&D
The availability of reliable, rapid diagnostics is key to reopening our economies. Canada has an opportunity to take a leadership role in accelerating the development of these tests through a coordinated Canadian response. The goal is to support researchers to build networks and find collaborators/industry partners to advance their ideas to clinical trial and mass production. To that end, Dr.